Ignite Creation Date:
2024-05-06 @ 4:23 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04975204
Status:
UNKNOWN
Last Update Posted:
2022-03-07
First Post:
2021-07-14
Brief Title:
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Organization:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Study Overview
Official Title:
A Phase I Clinical Trial Evaluating the Tolerance and Pharmacokinetics of TQB3909 Tablets in Patients With Relapsed or Refractory Advanced Malignant Tumors
Status:
UNKNOWN
Status Verified Date:
2022-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
TQB3909 is an inhibitor targeting at B-cell lymphoma BCL-2 protein By binding to BCL-2 protein TQB3909 releases Pro apoptotic proteins such as BCL-2-AnatagonistKiller 1BAK BCL-2 associated X BAX protein and BCL-2 associated death BAD protein promotes the release of cytochrome c from mitochondria phosphatidylserine eversion stimulates caspase 3 7 activity and caspase 3 9 cleavage and induces apoptosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None